• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Michael Fitzhugh

Michael Fitzhugh

Articles

ARTICLES

FDA approves Lilly and Incyte's baricitinib for second-line RA treatment

June 4, 2018
By Michael Fitzhugh
Despite an initial complete response letter and a challenging bout with members of the Arthritis Advisory Committee and FDA reviewers, Eli Lilly and Co. and licensor Incyte Corp. have gained the agency's approval for a 2-mg dose of the once-daily oral JAK 1/2 inhibitor baricitinib, the lower of two doses the partners have sought to market. It's now approved to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) inhibitors.
Read More

Madrigal's stock soars as promising midstage trial readout intensifies NASH race

June 1, 2018
By Michael Fitzhugh
Shares of Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) rocketed 145 percent higher to $265.61 Thursday on top-line 36-week phase II nonalcoholic steatohepatitis (NASH) data for MGL-3196. The drug showed statistically significant benefits in relative reduction of liver fat, the trial's primary endpoint, and NASH resolution, an accepted FDA regulatory endpoint, fueling new interest in the company's bid to conquer the obesity-linked condition for which no medicines are currently approved.
Read More

F-star, Denali forge ahead with antibody collaboration

May 31, 2018
By Michael Fitzhugh
A collaboration between Denali Therapeutics Inc. and F-star Ltd. aimed at enhancing the delivery of new therapies for neurodegenerative diseases across the blood-brain barrier gained new momentum Thursday. Denali exercised an option to acquire the first target of the partnership for $24 million up front and potential milestone payments of up to $447 million, composed of preclinical, clinical, regulatory and commercial milestones.
Read More

Iterum IPO raises $80M, as three other biopharmas file

May 29, 2018
By Michael Fitzhugh
May's IPO parade marched onward Friday, with anti-infectives specialist Iterum Therapeutics plc raising about $80 million in an offering that started below-range and inched downward from there. The company's 6.15 million-share (NASDAQ:ITRM) offering priced at $13 per share instead of the planned $14 to $16. Shares closed at $12.85 on Friday.
Read More

FDA rejects Recro Pharma's non-opioid pain drug

May 25, 2018
By Michael Fitzhugh
The FDA refusal to approve a new drug application for Recro Pharma Inc.'s lead non-opioid pain candidate, I.V. meloxicam, sent company shares (NASDAQ:REPH) plunging 54.7 percent lower to close at $5.36 on Thursday, amid what had been a flurry of precommercial preparations at the Malvern, Pa.-based company.
Read More

FDA's Gottlieb previews agency plans to tackle gene therapy challenges

May 24, 2018
By Michael Fitzhugh
Speaking to Alliance for Regenerative Medicine (ARM) board members at what he called a "key point" in the ascendancy of cell and gene therapies, FDA Commissioner Scott Gottlieb said his agency is working to address a number of challenges facing the nascent field. New guidance documents that will articulate a framework for the manufacturing and clinical development of gene therapies are already underway, he said, including the outline of potential accelerated approval endpoints for certain therapies.
Read More

Longeveron testing cell therapy as flu vaccine booster

May 23, 2018
By Michael Fitzhugh
Longeveron LLC, a Miami-based company developing allogeneic mesenchymal stem cell therapies (MSCs) for aging-related conditions, has landed a $750,000 grant from the Maryland Technology Development Corp. to support an ongoing trial examining the safety and efficacy of its bone-marrow-sourced cells to improve flu vaccine immune-response in elderly patients with aging frailty.
Read More

Rain Therapeutics to advance biomarker-driven NSCLC drug with $18.4M series A

May 22, 2018
By Michael Fitzhugh
Rain Therapeutics Inc., a startup planning a phase II test of an experimental small-molecule drug for people with EGFR and ErbB exon 20 insertion mutations in non-small-cell lung cancer, has closed a tranched $18.4 million series A round. The financing was led by Biotechnology Value Fund (BVF) and followed by Perceptive Advisors, Auckland Uniservices Ltd.'s Inventors Fund and other private investors. The series A round follows a $1 million convertible note financing the company completed in late-2017.
Read More

Dendreon seeks expanded role for Provenge in new early stage prostate cancer trial

May 21, 2018
By Michael Fitzhugh
The transnational Lazarus tale of Provenge (sipuleucel-T), a pioneering cellular immunotherapy from Dendreon Pharmaceuticals LLC, is opening what could be a significant new chapter with the initiation of a trial designed to prove the treatment can halt prostate cancer progression, reducing or delaying the need for definitive therapies such as surgery and radiation. Expected to begin enrolling later this year, top-line data from the study are due by 2023.
Read More

Worldmeds wins FDA approval for opioid withdrawal drug

May 18, 2018
By Michael Fitzhugh
US Worldmeds LLC has landed the first FDA approval of a non-opioid treatment for the management of opioid withdrawal symptoms, giving U.S. doctors a tool that has long helped U.K. doctors provide relief to patients going off the powerful medicines.
Read More
View All Articles by Michael Fitzhugh

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 23, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 20, 2025
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • Illustration of liver with DNA double helixes

    ASGCT 2025: Gene and cell therapies transform metabolic diseases

    BioWorld Science
    Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe